NBY — NovaBay Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00Annual income statement for NovaBay Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8.42 | 14.4 | 14.7 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 5.95 | 7.78 | 7.89 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 17.3 | 28.8 | 22.3 | 7.38 | 8.44 |
| Operating Profit | -8.86 | -14.4 | -7.6 | -7.38 | -8.44 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.82 | -10.6 | -9.64 | -8.75 | -33.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.82 | -10.6 | -9.64 | -8.75 | -33.2 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -5.82 | -10.6 | -9.64 | -7.22 | -22.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.56 | -16.3 | -16.7 | -8.61 | -22.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -640 | -1,036 | -586 | -14.9 | -5.56 |
| Special Dividends per Share |